Febrile Neutropenia Market, By Treatment Type, By Etiology, By Diagnostic Methods, By Risk Factors, By End User, By Country, and By Region – Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

REPORT HIGHLIGHT

The Febrile Neutropenia Market size was valued at US$ 11,123.54 Million in 2024, expanding at a CAGR of 4.0% from 2025 to 2032.
The Febrile Neutropenia market focuses on therapies, biologics, and supportive care solutions used to treat fever-induced low neutrophil counts in cancer patients receiving chemotherapy. The market is strongly influenced by the rising global cancer burden, which is increasing the number of immunocompromised patients at risk of serious infections. The rapid adoption of long-acting G-CSF therapies and biosimilars, which improve patient convenience and reduce hospitalization, is a major industry trend. However, high treatment costs and limited access to advanced biologics in low- and middle-income countries remain significant barriers to widespread adoption. Despite this, significant opportunities are emerging in precision medicine, where biomarkers and AI-powered risk prediction tools enable personalised neutropenia management. As oncology pipelines grow and healthcare systems prioritize infection prevention, the febrile neutropenia market shifts toward more innovative, patient-centered therapeutic solutions.

Febrile Neutropenia Market- Market Dynamics

Cancer Surge Driving Strong Growth in the Febrile Neutropenia Market
Rising global cancer incidence is a significant factor driving the febrile neutropenia market. As more patients receive chemotherapy, the risk of developing febrile neutropenia rises, driving demand for preventive and therapeutic interventions. According to the American Cancer Society (January 2022), the United States reported an estimated 1.9 million new cancer cases and over 609,000 cancer-related deaths, with common cancers such as lung, breast, prostate, and colorectal accounting for 43% of all diagnoses. The growing global cancer burden naturally results in a larger population of immunocompromised patients, making febrile neutropenia management critical. This growing clinical need is expected to drive market demand in the coming years, especially for biologics, G-CSF therapies, and advanced supportive care solutions.

Febrile Neutropenia Market- Segmentation Analysis:

The worldwide market is segmented on the basis of Treatment Type, Etiology, Diagnostic Methods, Risk Factors, End User, and Region.
Based on Risk Factors. Chemotherapy-induced neutropenia continues to dominate the febrile neutropenia market, owing to the widespread use of chemotherapy regimens that significantly suppress immune function and increase infection risks in cancer patients. This segment benefits from ongoing advances in supportive care, with biopharmaceutical companies actively developing and expanding access to long-acting G-CSF therapies that aid in treatment continuity and hospitalization reduction. For instance, on May 16, 2023, Amneal Pharmacesticals, lec, introduced FYLNETRA (pegfilgrastim pbbk), a biosimilar to Naulasta in a pre-filled single-dose syringe. PYLNETRA is used to treat fabrie neutropenia, which is common among patients undergoing chemotherapy.
Based on End User, Hospitals account for the largest end-user segment due to their extensive healthcare infrastructure, advanced oncology departments, and ability to manage complex treatment protocols. The high volume of cancer admissions, particularly among chemotherapy patients who are at high risk of developing neutropenia, reinforces hospitals' dominance in this market. These facilities have the specialized equipment, multidisciplinary expertise, and 24-hour monitoring capabilities needed to provide intensive neutropenia management, including biologics and supportive care treatments. While hospitals remain the primary setting for acute care, the broader neutropenia treatment landscape is expanding via digital and home-based platforms. For example, in 2022, CVS Health filled over 40,000 prescriptions for neutropenia therapeutics via its digital pharmacy platform, demonstrating how complementary care models are emerging to support hospital-based treatment pathways.

Febrile Neutropenia Market- Geographical Insights

North America has a number of factors that help this market grow more than other regions, owing to its advanced healthcare infrastructure and high cancer prevalence. The United States, in particular, dominates the region's market size and growth. The presence of major pharmaceutical companies, extensive R&D activities, and favorable healthcare policies all contribute to the region's dominance. Furthermore, the Middle East and Africa (MEA) region is gradually recognizing the importance of addressing febrile neutropenia, with approximately 5% of the global market share. The growth is being driven by rising cancer rates, improved healthcare infrastructure, and increased awareness among healthcare professionals. Regulatory bodies are beginning to put in place frameworks that will support the introduction of new therapies, paving the way for market expansion.

United States Febrile Neutropenia Market- Country Insights

The United States, is known for its high concentration of major players such as pharmaceutical and medical device companies. The presence of major players actively participating in clinical trials promotes the development of novel therapeutics and alternative treatment options. Furthermore, FDA approvals for the treatment of febrile neutropenia in the region are steadily increasing, which is expected to drive market growth. For example, on September 9, 2022, Spectrum Pharmaceuticals, Inc., a biopharmaceutical company focused on novel and targeted oncology therapies, received approval from the United States Food and Drug Administration (FDA) for ROLVEDON (eflapegrastim-nst) injection to reduce the incidence of infection, as manifested by febrile neutropenia.

Febrile Neutropenia Market- Competitive Landscape:

The Febrile Neutropenia Market is distinguished by a complex interplay of competitive dynamics, fueled by the rising prevalence of cancer and the subsequent increase in chemotherapy treatments. Key players like Amgen Inc., Celgene Corporation, Roche Holding AG, and Bristol-Myers Squibb Company are well-positioned to capitalize on their diverse portfolios and innovative capabilities. Amgen (US) focuses on improving its therapeutic offerings through ongoing research and development, whereas Roche (CH) emphasizes personalized medicine and targeted therapies. Bristol-Myers Squibb (US) is actively seeking strategic partnerships to strengthen its pipeline, indicating a shift toward collaborative innovation. Collectively, these strategies not only strengthen their market presence, but also shape a competitive environment that is increasingly reliant on innovation and strategic alliances.

Recent Developments:

In August 2025, Roche has announced a significant collaboration with a leading biotechnology company to develop a novel treatment for febrile neutropenia, which is set to begin clinical trials in early 2026. This strategic move demonstrates Roche's commitment to innovation and proactive approach to addressing unmet medical needs in the oncology field. By collaborating with a biotechnology partner, Roche not only improves its research capabilities but also positions itself to potentially gain a larger market share in the febrile neutropenia segment.
In September 2025, Amgen has launched a new digital platform aimed at increasing patient engagement and treatment adherence for febrile neutropenia. This initiative reflects Amgen's emphasis on digital transformation and its recognition of the value of patient-centered approaches to improving treatment outcomes. Amgen's use of technology is likely to strengthen its competitive advantage and foster deeper connections with both healthcare providers and patients.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL FEBRILE NEUTROPENIA MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Amgen Inc.
Sanofi S.A.
Bayer AG
Biogen Inc.
Ono Pharmaceutical Co., Ltd.
Merck & Co., Inc.
Pfizer Inc.
Teva Pharmaceutical Industries Ltd.
Novartis AG
Johnson & Johnson
AstraZeneca plc
AbbVie Inc.
Takeda Pharmaceutical Company Limited
Celgene Corporation
Roche Holding AG
Bristol-Myers Squibb Company
GlaxoSmithKline plc
Eli Lilly and Company
Gilead Sciences, Inc.
Ipsen S.A.
Others

GLOBAL FEBRILE NEUTROPENIA MARKET, BY TREATMENT TYPE- MARKET ANALYSIS, 2019 - 2032

Empirical Antibiotic Therapy
Supportive Care
Targeted Antibiotic Therapy

GLOBAL FEBRILE NEUTROPENIA MARKET, BY ETIOLOGY- MARKET ANALYSIS, 2019 - 2032

Fungal Infections
Gram-Negative Bacteria
Gram-Positive Bacteria
Viral Infections

GLOBAL FEBRILE NEUTROPENIA MARKET, BY DIAGNOSTIC METHODS- MARKET ANALYSIS, 2019 - 2032

Blood Cultures
Bone Marrow Aspiration
Imaging Tests

GLOBAL FEBRILE NEUTROPENIA MARKET, BY RISK FACTORS- MARKET ANALYSIS, 2019 - 2032

Transplant-Related Neutropenia
Chemotherapy-Induced Neutropenia
Genetic Disorders

GLOBAL FEBRILE NEUTROPENIA MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

Hospitals
Ambulatory Surgical Centers
Specialty Clinics
Others

GLOBAL FEBRILE NEUTROPENIA MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Sweden
Russia
Poland
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Indonesia
Thailand
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Rest of MEA Show more